FireGen Biomedicals Completed Tens of Millions of Yuan in B1 Round

FireGen Biomedicals has recently completed tens of millions of yuan in B1 round of financing. This round of financing is invested by Qingfeng Capital Innovation and Kechuang Angel Investment. 

The funds raised will be used to further promote the innovative integrated fully enclosed detection chip FireChip and POCT equipment into the clinical application stage, and to promote the extension of enterprise supply chain mergers and acquisitions.

FireGen is a globally operating biomedical company that builds a new generation of nucleic acid rapid diagnostic equipment, chips, and reagent R&D platforms for major diseases. The company currently has more than one hundred patents, and at the same time meets China's CFDA, EU CE, US FDA registration, high-standard large-scale GMP plant, and its products have entered 30 countries.

One of FireGen's core products is the integrated fully enclosed detection chip FireChip. It is reported that the application of FireChip can greatly reduce the requirements for laboratories and operators, can quickly cover small and medium cities, realize rapid diagnosis of various diseases, and even realize general screening in areas hardest hit by the epidemic, reduce the backlog of suspected patients, and effectively prevent Control epidemics or major diseases.

In terms of fighting the epidemic, the new SARS-CoV-2 nucleic acid detection freeze-dried powder kit independently developed by FireGen can exist in the state of freeze-dried powder while accurately detecting, getting rid of the limitations of cold chain storage and transportation, and reaching primary medical care.